ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Pre-Tax Margin

Income before tax as a percentage of revenue.

ImmunityBio, Inc.NASDAQ: IBRX

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin narrows to -377.9%

Pre-tax margin was -377.9% in Q3 FY2026, down 167.9 pp from a year earlier. On a trailing-twelve-month basis it was -607.9%, down 185.5 pp year over year. Over 3 fiscal years it widened by 173558.8 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-377.9%+71.7 pp QoQ
Last fiscal yearDec 2025
-310.4%+2495.0 pp YoY
LTMSep 2026
-607.9%-185.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-167.9 pp——
1 year+2495.0 pp——
3 years+173558.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-310.4%
Year-over-year change
+2495.0pp

Pre-Tax Margin vs competitors

How IBRX compares with its peers on the latest reported figures

  • IBRX's LTM Sep 2026 pre-tax margin of -607.9% is the 8th highest of the 9 companies compared; the peer median is -60.2%.
  • Its year-over-year change of -185.5 pp is the 8th highest of 9, against a peer median of +15.8 pp.
  • Over three fiscal years its change of +173558.8 pp compares with a peer median of -111.4 pp.
IBRX Competitors Peer median
Pre-Tax Margin for IBRX and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 20262.4% +26.8 pp+353.5 pp
IMCRImmunocore Holdings plcLTM Mar 2026-2.0% +4.8 pp+18.7 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-40.8% -32.9 pp+386.2 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-58.5% +100.5 pp—
BNTXBioNTech SELTM Jun 2026-61.9% -48.4 pp-111.4 pp
MRNAModerna, Inc.LTM Sep 2026-108.1% +33.9 pp-193.1 pp
IMTXImmatics N.V.LTM Mar 2026-577.4% -565.0 pp-435.5 pp
IBRXImmunityBio, Inc.LTM Sep 2026-607.9% -185.5 pp+173558.8 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-675.4% +2100.4 pp-685.2 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
NKTXNkarta, Inc.FY2025— ——
Peer median (excluding IBRX) -60.2%+15.8 pp-111.4 pp

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.